

PPAR-γ (phospho Ser112) Polyclonal Antibody

Catalog No: YP0316

Reactivity: Human; Mouse; Rat

Applications: WB;ELISA

Target: PPAR-γ

Fields: >>PPAR signaling pathway;>>AMPK signaling pathway;>>Longevity regulating

 $pathway; >> Osteoclast\ differentiation; >> Thermogenesis; >> Non-alcoholic\ fatty\ liver\ disease; >> Pathways\ in\ cancer; >> Transcriptional$

misregulation in cancer;>>Thyroid cancer;>>Lipid and atherosclerosis

Gene Name: PPARG

Protein Name: Peroxisome proliferator-activated receptor gamma

P37231

P37238

Human Gene Id: 5468

Human Swiss Prot

No:

Mouse Gene Id: 19016

Mouse Swiss Prot

No:

Rat Gene ld: 25664

Rat Swiss Prot No: 088275

Immunogen: The antiserum was produced against synthesized peptide derived from human

PPAR-gamma around the phosphorylation site of Ser112. AA range:78-127

Specificity: Phospho-PPAR-γ (S112) Polyclonal Antibody detects endogenous levels of

PPAR-γ protein only when phosphorylated at S112.

Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

Source: Polyclonal, Rabbit, IgG

1/3



Dilution: WB 1:500 - 1:2000. ELISA: 1:10000. Not yet tested in other applications.

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-

chromatography using epitope-specific immunogen.

Concentration: 1 mg/ml

Storage Stability: -15°C to -25°C/1 year(Do not lower than -25°C)

Observed Band: 60kD

Cell Pathway : Protein_Acetylation

Background: peroxisome proliferator activated receptor gamma(PPARG) Homo sapiens This

gene encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. PPARs form heterodimers with retinoid X receptors (RXRs) and these heterodimers regulate transcription of various genes. Three subtypes of PPARs are known: PPAR-alpha, PPAR-delta, and PPAR-gamma. The protein encoded by this gene is PPAR-gamma and is a regulator of adipocyte differentiation. Additionally, PPAR-gamma has been implicated in the pathology of numerous diseases including obesity, diabetes, atherosclerosis and cancer. Alternatively spliced transcript variants that encode different isoforms

have been described. [provided by RefSeq, Jul 2008],

Function: alternative products:Additional isoforms seem to exist, disease:Defects in

PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3)

[MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia., disease:Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension., disease:Defects in PPARG may be associated with colon cancer., disease:Defects in PPARG may be associated with susceptibility to obesity [MIM:601665]., disease:Variation in

PPARG is associated with carotid intimal medial thickness 1 (CIMT1) [MIM:609338]. CIMT is a measure of atherosclerosis that is independently

associated with traditional atherosclerotic cardiovascular disease

Subcellular Location:

Nucleus. Cytoplasm. Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation.


Expression: Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart

and liver. Also detectable in placenta, lung and ovary.


Products Images



Western Blot analysis of various cells using Phospho-PPAR- γ (S112) Polyclonal Antibody diluted at 1:500



- + phospho-peptide
- + non-phospho-peptide
- + + Paclitaxel (1uM, 24hours)



Western Blot analysis of PC-3 cells using Phospho-PPAR- γ (S112) Polyclonal Antibody diluted at 1:500